

# CITATION REPORT

List of articles citing

## Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety

DOI: 10.1016/j.jacc.2018.05.066

Journal of the American College of Cardiology, 2018, 72, 838-8

**Source:** <https://exaly.com/paper-pdf/71602068/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
78	2018 Korean Guideline of Atrial Fibrillation Management. <i>Korean Circulation Journal</i> , <b>2018</b> , 48, 1033-1080.	10.2	68
77	Edoxaban's Journey: From East Asia to the Globe, Back to East Asia. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 854-856	15.1	
76	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies. <i>Stroke</i> , <b>2019</b> , 50, 2819-2828	6.7	16
75	Safety and Effectiveness of Contemporary P2Y Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e012078	6	33
74	Increased risk of atrial fibrillation in patients with Behçet's disease: A nationwide population-based study. <i>International Journal of Cardiology</i> , <b>2019</b> , 292, 106-111	3.2	6
73	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 3295-3308	15.1	61
72	Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	6
71	Reply: Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2330-2331	15.1	
70	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 187-209	4.1	15
69	Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , <b>2019</b> , 50, 2245-2249	6.7	40
68	Visit-to-visit variability of metabolic parameters and risk of heart failure: A nationwide population-based study. <i>International Journal of Cardiology</i> , <b>2019</b> , 293, 153-158	3.2	14
67	Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Chest</i> , <b>2019</b> , 156, 529-543	5.3	62
66	Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 942-950	2.6	3
65	Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. <i>Stroke</i> , <b>2019</b> , 50, 1480-1489	6.7	8
64	Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. <i>Scientific Reports</i> , <b>2019</b> , 9, 6690	4.9	10
63	Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. <i>Stroke</i> , <b>2019</b> , 50, 1140-1148	6.7	24
62	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 919-931	15.1	46

61	Low Body Weight and Prescribing DOACs in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 932-934	15.1	1
60	Association between Atrial Fibrillation, Myocardial Infarction, Heart Failure and Mortality in Patients with Nontuberculous Mycobacterial Infection: a nationwide population-based study. <i>Scientific Reports</i> , <b>2019</b> , 9, 15503	4.9	3
59	Low Lipid Levels and High Variability are Associated With the Risk of New-Onset Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e012771	6	21
58	Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	16
57	Association of Total Reproductive Years With Incident Atrial Fibrillation, and Subsequent Ischemic Stroke in Women With Natural Menopause. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2019</b> , 12, e007428	6.4	7
56	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. <i>International Journal of Clinical Practice</i> , <b>2019</b> , 73, e13285	2.9	7
55	Understanding family involvement in body donation in Hong Kong: A qualitative study of registered donors and bereaved family members. <i>Health and Social Care in the Community</i> , <b>2020</b> , 28, 270-278	2.6	8
54	Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , <b>2020</b> , 25, 973-983	5.83	5
53	Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data. <i>Heart Failure Reviews</i> , <b>2020</b> , 25, 957-964	5	10
52	Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 533-547	3.8	33
51	Real-world observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , <b>2020</b> , 22, 831-832	3.9	14
50	The year in cardiology: arrhythmias and pacing. <i>European Heart Journal</i> , <b>2020</b> , 41, 619-625c	9.5	2
49	Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. <i>Stroke</i> , <b>2020</b> , 51, 416-423	6.7	20
48	Temporal trends of catheter ablation for patients with atrial fibrillation: A Korean nationwide population-based study. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2020</b> , 31, 2616-2625	2.7	2
47	Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. <i>American Heart Journal</i> , <b>2020</b> , 229, 81-91	4.9	5
46	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, I1-I12	1.5	2
45	Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel. <i>CJC Open</i> , <b>2020</b> , 2, 641-651	2	3
44	Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 132	5.4	5

43	Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry. <i>Future Cardiology</i> , <b>2020</b> , 16, 469-480	1.3	2
42	Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. <i>Open Heart</i> , <b>2020</b> , 7, e001232	3	13
41	Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e005894	5.8	5
40	Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. <i>Scientific Reports</i> , <b>2020</b> , 10, 1801	4.9	15
39	Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 1332-1338	3	17
38	Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. <i>CardioRenal Medicine</i> , <b>2020</b> , 10, 266-276	2.8	8
37	Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up. <i>BMC Cardiovascular Disorders</i> , <b>2020</b> , 20, 166	2.3	2
36	Impact of Hemoglobin Levels and Their Dynamic Changes on the Risk of Atrial Fibrillation: A Nationwide Population-Based Study. <i>Scientific Reports</i> , <b>2020</b> , 10, 6762	4.9	8
35	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)	9.5	1676
34	Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 31-39	6.4	3
33	Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 415-423	6.4	10
32	Differential Effect of Metabolic Health and Obesity on Incident Heart Failure: A Nationwide Population-Based Cohort Study. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 625083	5.7	3
31	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding. <i>Stroke</i> , <b>2021</b> , 52, 511-520	6.7	5
30	Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	1
29	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
28	Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 1	3.9	1
27	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , <b>2021</b> , 23, 1612-1676	3.9	99
26	Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). <i>Revista Espanola De Cardiología</i> , <b>2021</b> , 74, 437.e1-437.e116	1.5	3

25	Association between exercise habits and stroke, heart failure, and mortality in Korean patients with incident atrial fibrillation: A nationwide population-based cohort study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003659	11.6	4
24	Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. <i>European Heart Journal</i> , <b>2021</b> , 42, 4759-4768	9.5	10
23	Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	
22	Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study. <i>International Journal of Stroke</i> , <b>2021</b> , 17474930211029441	6.3	1
21	Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: A PRISMA-compliant article. <i>Medicine (United States)</i> , <b>2021</b> , 100, e26883	1.8	1
20	Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 625-631	15.1	10
19	Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences. <i>Egyptian Heart Journal</i> , <b>2021</b> , 73, 70	1.3	3
18	Focused Update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure. <i>International Journal of Heart Failure</i> , <b>2019</b> , 1, 4	1.3	32
17	Clinical Research from a Health Insurance Database: Practice and Perspective. <i>Korean Journal of Medicine</i> , <b>2019</b> , 94, 463-470	0.5	8
16	Cardiovascular Research Using the Korean National Health Information Database. <i>Korean Circulation Journal</i> , <b>2020</b> , 50, 754-772	2.2	54
15	Ticagrelor versus prasugrel in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , <b>2021</b> , 344, 25-30	3.2	0
14	The year in cardiology: arrhythmias and pacing?The year in cardiology 2019. <i>Cardiologia Croatica</i> , <b>2020</b> , 15, 132-145	0	
13	The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation. <i>Atherothrombosis</i> , <b>2020</b> , 28-43	0.3	
12	The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 18,	4.6	0
11	Dose Selection of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Non-Valvular Atrial Fibrillation. <i>Cardiovascular Prevention and Pharmacotherapy</i> , <b>2020</b> , 2, 1	0.2	
10	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	
9	Data_Sheet_1.PDF. <b>2020</b> ,		
8	Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4.1	0

7	XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia. <i>Advances in Therapy</i> ,	4.1	
6	Treatment and bleeding complications of cancer-associated venous thromboembolism: A Korean population-based study. <i>Thrombosis and Haemostasis</i> ,	7	1
5	Bioequivalence and Pharmacokinetic Study of 2 Edoxaban Tablets in Healthy Chinese Subjects.		
4	Stroke Prevention in Atrial Fibrillation. <b>2022</b> ,		
3	Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry. <b>2022</b> , 37,		o
2	Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants. <b>2022</b> , 17, e0278693		o
1	Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data. <b>2023</b> , 18, e0279297		o